Owlet, Inc.
NYSE:OWLTMedical - Devices
+$0.46 today
- Market cap
- $107.24M
- Beta
- 1.86
- P/E (TTM)
- -0.4
- EPS (TTM)
- -$12.67
Volume 0.64M
Average 0.24M
OWLT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Owlet, Inc.NYSE: OWLT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $3.96M rose 36.3% year over year, behind the +46.7% change in trailing-twelve-month research & development. Sequentially, it rose 8.8% from the prior quarter. Over 3 fiscal years it compounded at -20.4% a year.
Context
- Research & development amounted to 13.3% of revenue in FY2025, up 0.8 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +36.3% toward the trailing-twelve-month pace of +46.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 14.08M USD
- Year-over-year change
- +43.6%
- 4-year CAGR
- -10.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.08M | +43.6% |
| FY2024 | 2024-12-31 | 9.8M | -5.3% |
| FY2023 | 2023-12-31 | 10.35M | -62.9% |
| FY2022 | 2022-12-31 | 27.9M | +30.2% |
| FY2021 | 2021-12-31 | 21.43M | — |
Research & Development vs competitors
How OWLT compares with its peers on the latest reported figures
- OWLT's LTM Mar 2026 research & development of $15.13M is the 7th highest of the 10 companies compared; the peer median is $23.84M.
- Its year-over-year change of +46.7% is the 2nd highest of 10, against a peer median of -7.2%.
- Research & development amounts to 14.1% of revenue for OWLT, versus a peer median of 58.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $74.27M | +76.4% | +63.2% | — | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $70.12M | +24.4% | +57.8% | 3788.3% |
| LTM Mar 2026 | $31.62M | -19.6% | +9.2% | 6022.3% | |
| LTM Mar 2026 | $26.42M | +16.3% | +12.0% | 22.7% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $23.84M | -29.5% | +13.5% | — |
| LTM Mar 2026 | $18.78M | -12.5% | +2.2% | 58.2% | |
| LTM Mar 2026 | $15.13M | +46.7% | -20.4% | 14.1% | |
| LTM Mar 2026 | $13.34M | -7.2% | +1.9% | 38.8% | |
| LTM Mar 2026 | $5.47M | +1.0% | -21.9% | 9.5% | |
| LTM Mar 2026 | $5.46M | -7.8% | +691.2% | 106.3% | |
| Peer median (excluding OWLT) | $23.84M | -7.2% | +12.0% | 58.2% | |
Competitors are the stored peer set for OWLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75.84M | 69.2M | 54.01M | 78.06M | 105.71M |
| Cost of Revenue | 40.78M | 45.89M | 31.42M | 38.75M | 52.18M |
| Gross Profit | 35.06M | 23.31M | 22.59M | 39.31M | 53.53M |
| Gross Margin | 46.2% | 33.7% | 41.8% | 50.4% | 50.6% |
| Research & Development | 21.43M | 27.9M | 10.35M | 9.8M | 14.08M |
| Selling, General & Admin | 69.42M | 80.04M | 40.87M | 49.73M | 47.72M |
| Operating Expenses | 90.85M | 107.93M | 51.22M | 59.53M | 61.79M |
| Depreciation & Amortization | 1.13M | 2.67M | 2.21M | 1.38M | 590K |
| EBITDA | (42.71M) | (75.53M) | (27.49M) | (9.47M) | (35.64M) |
| EBITDA Margin | -56.3% | -109.1% | -50.9% | -12.1% | -33.7% |
| Operating Income | (55.79M) | (84.62M) | (28.63M) | (20.22M) | (8.26M) |
| Operating Margin | -73.6% | -122.3% | -53.0% | -25.9% | -7.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 27.83M | 1.1M | 3.19M | 1.63M | 3.42M |
| Other Income / Expenses | (15.88M) | 5.31M | (4.26M) | 7.74M | (31.39M) |
| Income Before Tax | (71.67M) | (79.31M) | (32.89M) | (12.48M) | (39.65M) |
| Pre-Tax Margin | -94.5% | -114.6% | -60.9% | -16.0% | -37.5% |
| Income Tax Expense | 31K | 29K | 10K | 54K | 28K |
| Net Income | (71.7M) | (79.34M) | (32.9M) | (12.54M) | (39.68M) |
| Net Margin | -94.5% | -114.6% | -60.9% | -16.1% | -37.5% |
| EPS (Basic) | (12.47) | (9.97) | (4.53) | (0.83) | (2.24) |
| EPS (Diluted) | (12.47) | (9.97) | (4.53) | (0.83) | (2.24) |
| Weighted Avg Shares | 7.87M | 7.95M | 8.28M | 15.11M | 562.5M |
| Weighted Avg Shares (Diluted) | 7.87M | 7.95M | 8.28M | 15.11M | 562.5M |
Owlet, Inc.
NYSE:OWLT
Intrinsic Alpha fair value
Locked
Current Price
$3.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.